Episode Details

In this episode of Global Economic Press, Alex Brady discusses a significant development in the telehealth industry with the launch of Ozari Health's nationwide platform. This New York-based telehealth company aims to make GLP-1 weight loss medications more accessible and affordable across the United States. By offering compounded Semaglutide starting at eighty-six dollars per month and compounded Tirzepatide starting at one hundred twenty dollars per month, Ozari Health is poised to reshape the landscape of weight management solutions. The platform provides a convenient and affordable option for patients, with branded medications like Ozempic, Wegovy, Mounjaro, and Zepbound available entirely online without hidden fees or long-term contracts.

Ozari Health was founded to address the challenges faced by individuals navigating the complex landscape of compounded GLP-1 providers. Unlike most telehealth platforms, Ozari offers patients a choice of pharmacy partners, ensuring transparent and standardized pricing. The company is committed to providing a seamless customer experience, with dedicated support staff and direct involvement from the founding team. Patients complete a short health assessment and receive a provider evaluation within twenty-four hours, with medications shipped directly to their homes if clinically appropriate. For more information, visit ozarihealth.com.